With a focus on Ophthalmology, Inomata Challening Lab is seeking new challenges in clinical research, digital health, and management. We await and welcome new members and business partners to open new frontiers in the field of ocular health care.
With a focus on Ophthalmology, Inomata Challening Lab is seeking new challenges in clinical research, digital health, and management. We await and welcome new members and business partners to open new frontiers in the field of ocular health care.
The term "challenge" evokes a positive spirit, almost conjuring tenacity and determination to achieve our goals. In Inomata Challenging Lab, we stray away from invalidating feedbacks that may reinforce negativity when met with difficult obstacles. Instead, we bolster our curiosity and perserverence together, giving constructive feedbacks and reminding ourselves of our motto to continue our challenges.
Both as a physician and a researcher myself, I continue my lifelong learning and commitment to bettering medicine through ongoing research and challenges together with a team that shares the same passion.
Disruptive Innovation, as the term conveys, refers to an innovation unbound by traditional concepts that can disrupt the current market and create a new value network. At Inomata Challenging Lab, we continue our novel research, striving to bring disruptive innovations to the field of medicine.
We have seven areas of interest that are being actively explored in our lab.
Not only participate we numerous interdisciplinary meetings, but Inomata Challenging Lab also pursues university start-up ventures and joint projects with an ultimate goal to achieve societal implementation of our research findings.
Cornea, the most anterior portion of our eye, must remain clear and void of any vasculature which allows light to pass without alteration. This transparency is crucial in maintaining visual acuity. To mitigate corneal abrasions and neovascularization brought on by trauma, infection, or autoimmune diseases, we are investigating new pharmacologic targets and topical medications. Additionally, we are pursuing research in new immunomodulatory agents to improve corneal transplantation outcomes.
Dry eye disease is one of the most prevalent ocular surface disease around the world, affecting approximately 20 million people in Japan alone and 1 billion worldwide. Borrowing principles of multiomics, mobile health (mHealth), artificial intelligence, and big data analysis, we aim to better elucidate the pathophysiology, variability, and heterogeneity of dry eye disease.
Hay fever is a highly prevalent disease affecting more than 30 million people in Japan and approximately 10-30% of the global population. Allergic conjunctivitis is a very common manifestation of hay fever, causing a wide range of discomfort to patients during high-pollen seasons. To better understand the pathophysiology and variability behind hay fever and allergic conjunctivitis, we are creating novel approaches to our investigation through utilizing multiomics, mobile health (mHealth), and big data analysis.
Ocular immunology is an area of study that our lab is venturing in. For various ocular diseases with a high component of immunology involved, such as corneal transplantation, allergic conjunctivitis, and dry eye disease, we seek to help widen our understanding of the immune dynamics in its pathogenesis through multiomics data and machine learning. In addition, our lab is currently undertaking studies on immunosenescence with a focus on interplay of T cells in the ocular microenvironment.
Through mouse models and human-derived samples, several multiomics studies are undergoing active investigation to elucidate pathophysiology of ocular diseases. Using smartphone-based mobile health (mHealth) methodologies and the extensive genomic data available in biobanks, we are differentiating ourselves from traditional approaches and are bringing in innovative ideas to the field.
Our labs is actively seeking new innovations using digital health, particularly with artificial intelligence to open new frontiers in advanced image analyses and development of Software as Medical Devices (SaMDs).
With a background in business administration from Boston University, I have always had passion and fascination in maximizing healthcare quality and efficiency, as well as the recent movement in Japan towards a physician work style reform. InnoJin represents the team's and my collective efforts to implement our learnings and to research how to improve workflow that is tailored to each healthcare business.
